Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.79 USD
Change Today +0.18 / 2.37%
Volume 831.0K
TXMD On Other Exchanges
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

therapeuticsmd inc (TXMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/23/15 - $8.83
52 Week Low
12/15/14 - $3.44
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for THERAPEUTICSMD INC (TXMD)

Related News

No related news articles were found.

therapeuticsmd inc (TXMD) Related Businessweek News

No Related Businessweek News Found

therapeuticsmd inc (TXMD) Details

TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, as well as duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The company also focuses on conducting the clinical trials for hormone therapy pharmaceutical products that are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. In addition, it manufactures and distributes branded and generic prescription prenatal, as well as OTC vitamins. TherapeuticsMD markets its products primarily through a direct national sales force to health care providers, as well as directly through its Website. The company was founded in 2008 and is headquartered in Boca Raton, Florida.

100 Employees
Last Reported Date: 03/12/15
Founded in 2008

therapeuticsmd inc (TXMD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $550.0K
President, Secretary and Director
Total Annual Compensation: $350.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $345.0K
Chief Strategy Officer and Executive Vice Pre...
Total Annual Compensation: $213.2K
Vice President of Finance
Total Annual Compensation: $150.0K
Compensation as of Fiscal Year 2014.

therapeuticsmd inc (TXMD) Key Developments

TherapeuticsMD, Inc. Approves Amendment to Articles of Incorporation

TherapeuticsMD, Inc. announced that its 2014 annual meeting of stockholders held on June 11, 2015 approved an amendment to the amended and restated articles of incorporation of the company to increase the number of authorized shares of Company common stock from 250,000,000 shares to 350,000,000 shares.

TherapeuticsMD, Inc. Ratifies Appointment of Grant Thornton, LLP as the Independent Auditor for the Year Ending December, 31, 2015

TherapeuticsMD, Inc. announced that its 2014 annual meeting of stockholders held on June 11, 2015 ratified the appointment of Grant Thornton, LLP, an independent registered public accounting firm, as the independent auditor of the company for the fiscal year ending December, 31, 2015.

TherapeuticsMD, Inc. Completes Enrollment in the Rejoice Trial

TherapeuticsMD, Inc. announced that the company has completed patient enrollment in The Rejoice Trial, a phase 3 clinical trial of TX-004HR (estradiol in VagiCap™) to evaluate multiple doses of an investigational, applicator-free vaginal estradiol for the treatment of pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. TX-004HR is an investigational bio-identical estradiol softgel capsule administered vaginally without the need for an applicator. The Rejoice Trial is also collecting efficacy data on vaginal dryness, and vaginal and/or vulvar itching or burning. Trial Design: A pivotal safety and efficacy study, the Rejoice Trial is a randomized, multicenter, double-blind, placebo-controlled study evaluating three strengths of TX-004HR – 4 mcg, 10 mcg and 25 mcg. The 4 mcg strength represents a new low-dose option. The 12-week trial enrolled over 700 participants in approximately 100 sites across the United States and Canada.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXMD:US $7.79 USD +0.18

TXMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation TXMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 76.4x
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 77.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAPEUTICSMD INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at